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Abstract
Purpose: To assess patient views regarding the value of genetic counselling for familial pancreas cancer in the
absence of predictive genetic testing. 
Patients and methods: At-risk adults with three or more relatives with pancreas cancer received genetic counselling
prior to research screening via endoscopic ultrasound. Questionnaires were mailed after the visit to assess
perceived value of the counselling session. 
Results: Ninety-three percent of respondents felt genetic counselling for pancreas cancer was helpful despite
the lack of a causative gene, while only 7% felt that it should not be offered until such a gene is discovered.
Over half of respondents believed the pancreas cancer in their family was caused by a gene mutation, and
42% thought they had inherited the mutation. The average perceived lifetime risk of developing pancreas cancer
was 51%, and 87% of respondents would ultimately seek predictive genetic testing. When more information is
gained, 89% would be interested in another genetic counselling session, and 82% would recommend current
genetic counselling for pancreas cancer to a friend or relative with a family history of the disease. 
Conclusion: Despite the lack of an identified major causative gene for pancreas cancer, respondents found
genetic counselling for this malignancy to be helpful. These patients perceive their personal cancer risk to be
high, and would seek predictive genetic testing if it were available. Referral for genetic counselling should be
offered to appropriate individuals.
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Introduction
In its early days, genetic counselling was primarily
offered to diagnose individuals with multiple congenital
anomalies and to assess reproductive risk. With the
discovery of genetic causes for various diseases, the
scope of genetic counselling has broadened to include
adult-onset disorders such as cancer. One challenge
of genetic counselling is to recognize the specific
syndrome affecting a particular individual, which can
be accomplished either clinically through the
recognition of physical features or constellation of
diseases, or molecularly through the analysis of genes
or proteins. Once a diagnosis is made, various
health-related risks to the patient and his or her family
members may be identified. Additionally, the pattern
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of inheritance is usually known, thereby allowing the
genetic counsellor to provide recurrence estimates.
Such estimates allow patients to make informed choices
regarding health care and reproduction. Arguably,
genetic counsellors are better able to facilitate patient
decision-making when a definitive diagnosis can be
made. In the absence of definitive information,
however, the genetic counsellor still has the task of
assisting the patient to make decisions and adjust to
the disorder despite the uncertainty. 
The discovery of the BRCA1 and BRCA2 genes in
the 1990's has allowed health care providers to identify
the “cause” of breast cancer in a subset of patients.
For individuals affected with breast cancer, genetic
testing for these two genes can be used to estimate the
likelihood of future primary cancers, thereby potentially
influencing medical management. Predictive testing is
also available to unaffected family members,
distinguishing those that require intensive screening or
consideration of risk-reduction measures from those
that are at general population risk for cancer and do
not require excess care. Most health care providers
view such delineation as a way of maximising the
benefits of various medical services. 
Numerous studies have assessed the impact of
genetic counselling for breast cancer from the perspective
of the at-risk patient, including effect on risk perception,
anxiety and psychological affect. Three meta-analyses
demonstrated that genetic counselling for hereditary
breast cancer increases accuracy of risk perception and
decreases generalized anxiety without an adverse impact
on affective outcomes [1-3]. Although most analyses
have focused on genetic counselling, genetic testing for
BRCA1 and BRCA2 was clinically available at the time
of study. Therefore, patients presumably had the
opportunity to pursue predictive testing. Furthermore,
genetics providers were able to provide numerical cancer
risk estimates to patients using models developed by
Claus and Gail [4, 5]. The Claus model predicts breast
cancer risk based on affected first and second-degree
relatives and their respective ages at diagnosis. The Gail
model, while only including affected first-degree relatives
and not distinguishing between early and late-onset, also
incorporates patient age, race, reproductive history and
breast biopsy history. The advantage of these models is
the ability to provide patients with personalised risk
estimates. 
Questions surround the utility of genetic counselling
for diseases for which the causative genes have not yet
been identified, such as pancreas cancer. As much as
10% of pancreas cancer may be hereditary, yet there is
no currently available genetic testing and lifetime risk
estimates cannot be accurately provided in the
overwhelming majority of cases. One wonders whether
these at-risk patients have the same responses to genetic
counselling as individuals who receive more personalised
estimates and have the option of potentially informative
genetic testing. Furthermore, it is unknown whether they
find genetic counselling to be meaningful in the absence
of such personalised information. 
Klein [6] showed evidence of a rare major gene
influencing risk for pancreas cancer; Klein [7] was also
able to calculate standardised incidence ratios for
individuals who have one, two or three first-degree
relatives affected with pancreas cancer. Although these
data may be used to provide personalised risk
assessment to a small subset of familial pancreas cancer
families, no data (such as the Claus or Gail models)
currently exist to offer risk estimates to individuals with
a more diffuse family history. This calls into question the
value of genetic counselling for pancreas cancer. 
We sought to assess the value of genetic
counselling for familial pancreas cancer by surveying
at-risk individuals who had received such counselling.
The goal was to determine participants' views on the
utility of genetic counselling in the absence of an
identified major causative gene, interest in predictive
genetic testing once it becomes available, and cancer
risk perception based on family history. 
Patients and methods
Adults with no personal history of pancreas cancer,
but with three or more biological relatives with pancreas
cancer (of whom at least one was a first-degree relative)
were eligible to participate in a pancreas cancer
screening study. Participants had to be at least 40 years
old or no more than 10 years younger than the
youngest diagnosis of pancreas cancer in their family.
Screening entailed computed tomography imaging (CT)
and endoscopic ultrasound (EUS), and, if indicated,
endoscopic retrograde cholangiopancreatography
(ERCP). The entire protocol is outlined by Canto [8]. 
Genetic counselling was provided to all participants
prior to invasive screening. All participants were
counselled by one genetic counsellor (JA), usually with
one cancer genetics physician in attendance (CG).
Subjects received a letter following the visit which
summarised information discussed at the counselling
session. The content of the counselling session included
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a review of the family history that was previously collected
and confirmed by the National Familial Pancreas Tumor
Registry (NFPTR), a description of features suggestive of
a hereditary cancer syndrome and a general explanation
of autosomal dominant inheritance. Each pedigree was
then examined for characteristics of five hereditary
syndromes known to be associated with an increased
risk for pancreas cancer: (1) hereditary breast and
ovarian cancer (BRCA2), (2) familial atypical multiple
mole and melanoma syndrome (FAMMM), (3) hereditary
non-polyposis colorectal cancer (HNPCC), (4) Peutz-
Jeghers syndrome (PJS) and (5) hereditary pancreatitis.
The general features of each syndrome were discussed
with the patient, and suggestive family history, or lack
thereof, was emphasized. Genetic testing is commercially
available for each of these syndromes, but was not
provided as part of this study; however, participants were
informed if their family history was suggestive of any of
the above-named syndromes, and were offered a clinical
appointment with our service to pursue testing. 
The study population contained two groups with
a total ”n” of 69. Group 1 (seen September 2000
through June 2001) consisted of participants
counselled prior to the publication of data indicating
the presence of BRCA2 mutations in families with
pancreas cancer in the absence of breast and/or
ovarian cancer. Group 2 (March 2002 through
February 2004) was seen after the publication of these
data; thus, their counselling differed slightly. Evaluation
of the counselling process was conceived after
completion of counselling for group 1, so this group
was analysed separately to account for differences in
counselling and time to follow-up. 
There were 20 counsellees in group 1. Each was
contacted by telephone to determine his or her willingness
to complete a short, written questionnaire regarding the
counselling session. Fifteen agreed to participate while
five did not respond to our initial telephone message.
Questionnaires were only mailed to those 15 who actively
agreed to participate, making the ”n” for group 1 fifteen.
The average time elapsed between counselling and
mailing of the questionnaire was approximately one year.
Fifty-four group 2 participants were asked at the
conclusion of counselling if they wished to complete the
questionnaire. All agreed to participate, making the ”n”
for group 2 fifty-four. The average time elapsed between
counselling and mailing of the questionnaire was
approximately one month. 
Questionnaire responses were anonymous and
returned in postage-paid envelopes. Six demographic
questions included gender, age, race, marital status,
education and annual household income. Eighteen
evaluative statements were based on a 5-point Likert scale,
ranging from “strongly agree” to “strongly disagree” (see
Appendix). Four open-ended questions ascertained
perceived lifetime risk of pancreas cancer, the most and
least useful aspects of the genetic counselling session and
any additional comments. Estimated time to complete the
questionnaire was 10 minutes. 
Quantitative data were analysed using Microsoft
Access and Excel. Statistical analysis was performed with
Chi-square tables. Qualitative data, such as free text
comments, were analysed thematically by inspection. 
This study was approved through the Johns Hopkins
Medicine Institutional Review Board and Office of
Human Subjects Research. 
Results
Forty-five completed questionnaires were received
out of 69 sent, for a response rate of 65%. There was
no difference in response rate between groups 1 and
2 or males and females. Educational background was
not collected prior to the questionnaire, so response
rate based on education level could not be computed.
Characteristics of the respondents are presented in
Table 1, and include the average number of relatives
with pancreas cancer per respondent. Twenty-one of
the respondents also had a family history of breast
and/or ovarian cancer. Among them, two were
suspicious for hereditary breast and ovarian cancer,
while none were strongly suggestive of FAMMM,
HNPCC, PJS or hereditary pancreatitis. 
Six questions ascertained participant views regarding
genetic counselling for familial pancreas cancer. Overall
responses were favourable, indicating that respondents
found the session to be beneficial. Groups 1 and 2 were
Table 1. Characteristics of 45 respondents
Characteristic Percent
gender male (44%); female (56%) 
marital status married (82%) 
education college (18%); graduate school (58%) 
average age 56 years (range: 39-81) 
average # PC per family 3.68 (range: 3-7) 
PC = pancreas cancer
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Fig. 1. Patient views on genetic counselling for familial pancreas cancer
The genetic counselling session was helpful to me.
I would have preferred to have only the endoscopy procedure.
Genetic counselling for pancreas cancer is helpful, 
even if the ”pancreas cancer gene” has not been discovered. 
Genetic counselling should not be offered until 
the “pancreas cancer gene” has been found.
I would be interested in another genetic counselling session 
when more information is learned.
I would recommend genetic counselling for pancreas cancer 
to a friend or relative at increased risk for pancreas cancer. 
strongly agree                   somewhat agree
0%           20%         40%           60%          80%         100%
Fig. 2. Patient views on genetic testing for familial pancreas cancer
I do not feel that current genetic testing is likely to help me.
Even though the ”pancreas cancer gene” has not been found, 
I want to get genetic testing for one or more of the syndromes
discussed during genetic counselling.
If the ”pancreas cancer gene” were found, I would want to be tested for it. 
0%           20%         40%           60%          80%         100%
strongly agree                  somewhat disagree
somewhat agree               strongly disagree
neutral
very similar, but group 1 respondents were more likely
to prefer only the endoscopy procedure and not genetic
counselling (p≤0.025) and were less likely to find
genetic counselling helpful in the absence of an
identified ”pancreas cancer gene” (p≤0.05). There were
no significant differences between males and females
or varying educational levels. Combined responses are
presented in Figure 1. 
Three questions ascertained participant view
regarding genetic testing for familial pancreas
cancer. Respondents were neutral on the ability of
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Fig. 3. Patient perception that family history is due to an inherited gene mutation
I think that the pancreas cancer 
in my family is caused by a gene mutation.
I think I inherited a gene mutation that causes pancreas cancer. 
strongly agree              somewhat disagree
somewhat agree          strongly disagree
neutral
0%                         20%                         40%                        60%
currently available testing to help them, but would
want to be tested once the ”pancreas cancer gene”
is discovered. There were no significant differences
between groups 1 and 2 or varying educational
levels. Males and females were similar, though
females were less inclined to pursue currently
available genetic testing (p≤0.05). Combined
responses are presented in Figure 2. 
Two questions ascertained participant perception of
their risk of developing pancreas cancer, and respondents
generally felt that they were at increased risk for this
malignancy. There were no significant differences between
groups 1 and 2, males and females or differing
educational levels on these two evaluative questions;
however, responses to an open-ended question asking
participants to quantify their risk perception resulted in
a significant difference between males and females. The
mean lifetime risk estimate for all respondents was 50.8%
(range 1% to 100%), with a mode of 50% (n=13). Males
estimated a 38% lifetime risk while females estimated
a 59% lifetime risk (p≤0.01). Combined responses are
presented in Figure 3. 
Respondents cited explanation of the inheritance
process, understanding cancer risk and contribution to
general knowledge as the most useful aspects of the
genetic counselling sessions. The least useful aspects
were the limitations in the current state of knowledge
and inability to provide personalised risk estimates
rather than empiric risks. 
Discussion
Respondents were largely in favour of genetic
counselling for familial pancreas cancer, as more than
80% felt that it was helpful and agreed that genetic
counselling should continue to be offered despite the
inability to identify a major causative gene for this
malignancy. Most respondents desired another genetic
counselling session when more information is learned,
and cited the lack of current knowledge as their biggest
frustration. Although several respondents desired more
personalised cancer risk assessment, they reported
satisfaction with a better understanding of inheritance
patterns and the various hereditary syndromes
associated with pancreas cancer. 
From these responses, one can conclude that
individuals at increased risk for pancreas cancer benefit
from genetic counselling, and that it should be accessible
to appropriate individuals. Oncologists and internists who
care for patients at risk for pancreas cancer should offer
them a referral for genetic counselling by a qualified
health care provider. Giardiello demonstrated that patients
receiving genetic counselling from a provider less familiar
with hereditary cancer syndromes often received
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inadequate counselling and would have been given
incorrectly interpreted genetic test results [9]. Thus,
a consultation with a specialty genetics clinic is
recommended. The National Society of Genetic
Counselors, Inc. maintains a directory of genetic
counsellors at http://www.nsgc.org. Another source is
the Cancer Genetics Services Directory by the National
Cancer Institute at http://www.cancer.gov/search/
geneticsservices/. 
As indicated, there were few differences between
groups 1 and 2. However, those participants seen an
average of a year prior to completion of the
questionnaire were more likely to prefer only the
endoscopy procedure, and were less likely to find the
counselling helpful in the absence of available genetic
testing. The majority of these individuals have had
a second endoscopy procedure since their initial visit,
as the screening study strives to evaluate participants
annually. Therefore, the combination of the time elapsed
and additional participation may account for the
variation in group responses to these two statements. 
Respondents' views on predictive genetic testing for
hereditary pancreas cancer varied more. Two-thirds of
respondents were either neutral or felt that currently
available genetic tests were unlikely to be of benefit to
them; however, almost half of all respondents were
interested in testing for one of the syndromes discussed.
This indicates a desire to explore opportunities to refine
risk, no matter how small the likelihood of success. The
need to refine risk is further exemplified by the 87% of
respondents desiring testing once the ”pancreas cancer
gene” is discovered. 
The 5-year survival rate for patients with pancreas
cancer is 12% to 20%, if resectable, and less than 5%
if unresectable. The American Society of Clinical
Oncology recommends that genetic testing be offered
if the patient has a personal or family history suggestive
of a hereditary cancer syndrome, a genetic test is
available that can be adequately interpreted, and the
results will impact diagnosis or medical management of
the patient and/or relatives [10]. Given the lack of
proven screening for pancreas cancer, as well as the
morbidity associated with prophylactic pancreatectomy,
one could argue that predictive genetic testing for this
malignancy should not necessarily be offered upon the
discovery of a major causative gene. Rather, it should
coincide with the availability of a safe and effective
method to reduce the risk of advanced disease. Despite
informed consent prior to participating in this screening
study, respondents may have felt falsely reassured that
their participation had a high likelihood of preventing
advanced disease, thus explaining their desire to
undergo genetic testing. However, desire to undergo
genetic testing does not always equate with follow
through, as has been demonstrated in individuals at
increased risk for Huntington's disease, a neurological
disorder with a devastating outcome and no effective
intervention. Prior to the discovery of the associated
gene, 57-84% of individuals at risk for Huntington's
disease expressed a desire for predictive testing, while
only 5-24% actually underwent such testing once it
became available [11]. Therefore, once a major
causative gene is discovered for pancreas cancer, the
desire for predictive testing is anticipated to decrease
from the 87% reported here. 
Regarding risk perception, only 3 of 45 (7%)
respondents felt that the pancreas cancer in their family
was unlikely to have been caused by a gene mutation.
By contrast, over half of respondents felt that their
family history was caused by a gene mutation, while
one-third remained neutral. These results are as
expected, as this is a group of people who sought out
screening, thereby indicating a higher anxiety level
about developing pancreas cancer. Individuals who
do not suspect a hereditary aetiology to their family
history are arguably less likely to participate in a study
that poses a financial burden and the potential for an
adverse complication secondary to the procedure. 
When asked if they thought they had inherited the
predisposition to pancreas cancer, nearly half of all
respondents were neutral, while only 4 of the 45 (9%)
respondents believed they had not inherited it. Of note,
among these latter four, two had responded that the
cancer in their family was unlikely to be due to a gene
mutation, thereby maintaining a consistent opinion.
There are two potential explanations for the large
neutral response to this question. One possibility is that
the participants understood the 50% risk associated
with autosomal dominant inheritance. The second
possibility is that the respondents were unwilling to
”commit” to a response, maintaining hope that they
actually had not inherited the predisposition despite
fear that they had. Overall, the response to this question
was somewhat surprising, as one would expect more
respondents to suspect they were at increased risk based
on their participation in unproven screening. 
When asked to quantify risk perception, the mean
lifetime estimate was approximately 50%. This is much
greater than a geneticist would presume; although there
is evidence of a ”pancreas cancer gene”, the penetrance
is thought to be significantly below 100%. Therefore,
Jennifer E. Axilbund et al
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participant risk perception may be due to incomplete
understanding of autosomal dominant inheritance, or
due to a more basic perception of chance, such as,
”either I will, or will not, develop pancreas cancer”.
Regardless, these results are consistent with previous
reports focusing on individuals at increased risk for breast
or colon cancer. Such research demonstrated that
individuals at all levels of risk for cancer overestimate their
own cancer risk, and that risk perception is not greatly
influenced by genetic education and counselling [12].
Furthermore, subjects' decisions regarding genetic testing
were primarily influenced by their perceived risk rather
than actual risk status [12], which may explain why 87%
of our participants ultimately desire predictive genetic
testing. Also of interest was the difference in perceived
lifetime risk between males and females in our study, with
females estimating risk to be almost 20% higher than
males. However, this is also consistent with previous
research indicating that females, in general, perceive their
cancer risk to be higher than males do [13, 14]. 
The findings presented here are preliminary, and as
such have several limitations. First, the sample size is
small. Pancreas cancer is considered to be rare, and only
10% of pancreas cancer is likely to be hereditary.
Therefore, there is not a large population of at-risk
individuals from which to draw. Second, participants were
ascertained through the screening study, and did not
specifically seek out genetic counselling. Although this
has the advantage of potentially being a less biased
group, it is unknown whether individuals seeking clinical
genetic counselling (i.e. requiring health insurance or
self-payment) would have similar views. Third, the
responses may be biased toward participants who
favoured genetic counselling for familial pancreas cancer.
Perhaps those who did not respond did not find the
session to be valuable. Fourth, the participants were
predominantly very well-educated, upper-middle class
Caucasians. This was an uncontrollable consequence of
the endoscopy screening study, which required that
interested individuals travel, at their own expense, to the
lone research site. In addition, certain components of the
procedure were not covered by study funds, requiring that
the patient self-pay or involve health insurance, thereby
potentially eliciting a significant financial contribution on
the part of the participant. Finally, prospective participants
also needed to learn of the study's existence in the first
place, which was not highly advertised due to a large
pool of interested families already enrolled in a research
registry. Furthermore, awareness of the registry, itself, is
often gained through familiarity with the Internet or other
resources, as 55% of registry families are self-referred
versus joining at the recommendation of a health care
provider. As a result, it is unknown whether individuals of
differing socioeconomic status would view genetic
counselling for pancreas cancer as favourably as those
in the study described. 
To address these limitations, as well as measure the
psychological impact of genetic counselling for
pancreas cancer on at-risk family members,
a multi-centre consortium has been established. By
involving more institutions, screening and genetic
counselling can be offered to individuals of varying
backgrounds with two goals: one, to improve screening
for this deadly disease, and two, to determine the value
of genetic counselling to a more diverse population. 
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APPENDIX
1) I knew beforehand that I would receive genetic
counselling as part of my research visit. 
2) Before genetic counselling, I had already read or heard
a fair amount about hereditary pancreas cancer. 
3) The genetic counselling session was helpful to me. 
4) I would have preferred to have only the endoscopy
procedure and not genetic counselling. 
5) I would have preferred more information about
hereditary pancreas cancer. 
6) Scientists do not currently know enough about
hereditary pancreas cancer to help me. 
7) Even though the ”pancreas cancer gene” has not been
found, I still want to get genetic testing for one or more
of the syndromes discussed during genetic counselling. 
8) I do not feel that current genetic testing is likely to
help me. 
9) I would recommend genetic counselling for pancreas
cancer to a friend or relative with a family history of
pancreas cancer. 
10) The genetic information was too complex. 
11) The written summary of the visit was useful. 
12) I will share the written summary with my family
members. 
13) I think genetic counselling for pancreas cancer is
helpful, even if the “pancreas cancer gene” has not
been found. 
14) If the ”pancreas cancer gene” were found, I would
want to be tested for it. 
15) I do not think genetic counselling should be offered
for pancreas cancer until the ”pancreas cancer gene”
has been found. 
16) I would be interested in another genetic counselling
session when more information is learned about
pancreas cancer. 
17) I think that the pancreas cancer in my family is caused
by a gene mutation. 
18) I think I inherited a gene mutation that causes
pancreas cancer. 
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